Eli Lilly expands neuroscience pipeline with $1B acquisition of SiteOne therapeuticsProactive Investors • 05/27/25
Breaking The Pain Barrier: Lilly's Acquisition Of SiteOne Aims For Opioid AlternativesBenzinga • 05/27/25
Weight-loss drugs like Ozempic and Wegovy continue to be in high demand—and expensive. Are prices likely to come down soon?WSJ • 05/27/25
Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual MeetingPRNewsWire • 05/22/25
Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugsCNBC • 05/21/25
Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's diseasePRNewsWire • 05/21/25
Eli Lilly and Company (LLY) BofA Securities 2025 Health Care Conference Call TranscriptSeeking Alpha • 05/15/25
2 Stocks That Plummeted During President Trump's First 100 Days in Office, and Where They Could Be HeadedThe Motley Fool • 05/15/25
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?Zacks Investment Research • 05/14/25
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.Barrons • 05/13/25
Why Lilly (LLY) International Revenue Trends Deserve Your AttentionZacks Investment Research • 05/13/25